BC Week In Review | Jan 19, 2018
Company News

BioNTech, Scancell to discover TCR therapies for cancer

BioNTech AG (Mainz, Germany) and Scancell Holdings plc (LSE:SCLP; FSE:SCP) partnered to identify and develop T cell receptor (TCR) therapies to treat cancer. The partners plan to identify TCRs specific for citrullinated epitopes from vimentin...
BC Extra | Oct 11, 2017
Company News

Management tracks: Aerpio, Scancell, TCR2

Ophthalmic company Aerpio Pharmaceuticals Inc. (OTCQB:ARPO) named Stephen Hoffman CEO, effective Dec. 1, 2017. He succeeds Aerpio founder Joseph Gardner, who will remain its president. Hoffman was a senior advisor at PDL BioPharma Inc. (NASDAQ:PDLI),...
BC Week In Review | Feb 3, 2017
Company News

Scancell, Bonnie J. Addario Lung Cancer Foundation, Addario Lung Cancer Medical Institute deal

Scancell and the nonprofits partnered to conduct a Phase I/II trial of Scancell's SCIB2 in patients with non-small cell lung cancer (NSCLC). The trial will start in 2018 and will be completed about 18 months...
BioCentury | Jul 11, 2016
Finance

Ground up

Steve Edelson, Senior Editor   As the third quarter gets under way, biotech is shaking off the hangover of the Brexit vote while facing the overhang of the November election in the U.S. Fifteen bankers...
BC Week In Review | Jun 27, 2016
Clinical News

SCIB1: Phase I/II halted

Scancell suspended dosing in the open-label, dose-escalation, U.K. Phase I/II SCIB1-001 trial evaluating up to 8 mg intramuscular SCIB1 given at weeks 0, 3, 6, 12 and 24 after the company’s analysis of the stored...
BC Week In Review | Apr 4, 2016
Financial News

Scancell completes placing and open offer

Scancell Holdings plc (LSE:SCLP; Xetra:SCP), Nottingham, U.K.   Business: Cancer   Date completed: 2016-04-01   Type: Placing and open offer   Raised: L6.1 million ($8.7 million)   Shares: 36 million   Price: 17p   Shares...
BC Week In Review | Mar 28, 2016
Company News

Scancell, Karolinska Institute deal

Scancell and the institute partnered to use Scancell’s Moditope technology to evaluate citrullinated proteins to treat cancer and rheumatoid arthritis (RA). Scancell’s Moditope technology stimulates production of CD4+ T cells using citrullinated tumor-associated peptide epitopes...
BC Week In Review | Sep 21, 2015
Company News

ImmunID, Scancell deal

The companies will use ImmunID’s ImmunTraCkeR test to predict which patients will respond to Scancell’s SCIB1 , a cancer vaccine comprising the melanoma antigen tyrosinase-related protein 2 ( TRP-2 ; TYRP2 ; DCT ) and two helper T...
BC Week In Review | Jul 27, 2015
Clinical News

SCIB1: Completed Phase I/II enrollment

Scancell completed enrollment of 35 patients with resected stage III/IV metastatic melanoma in an open-label, dose-escalation, U.K. Phase I/II trial evaluating 4 mg intramuscular SCIB1 given at weeks 0, 3, 6, 12 and 24. Scancell...
BC Week In Review | Jun 8, 2015
Clinical News

SCIB1: Updated Phase I/II data

Updated data from 16 patients with fully resected stage III/IV metastatic melanoma in an open-label, U.K. Phase I/II trial showed that 4 mg intramuscular SCIB1 given at weeks 0, 3, 6, 12 and 24 led...
Items per page:
1 - 10 of 57
BC Week In Review | Jan 19, 2018
Company News

BioNTech, Scancell to discover TCR therapies for cancer

BioNTech AG (Mainz, Germany) and Scancell Holdings plc (LSE:SCLP; FSE:SCP) partnered to identify and develop T cell receptor (TCR) therapies to treat cancer. The partners plan to identify TCRs specific for citrullinated epitopes from vimentin...
BC Extra | Oct 11, 2017
Company News

Management tracks: Aerpio, Scancell, TCR2

Ophthalmic company Aerpio Pharmaceuticals Inc. (OTCQB:ARPO) named Stephen Hoffman CEO, effective Dec. 1, 2017. He succeeds Aerpio founder Joseph Gardner, who will remain its president. Hoffman was a senior advisor at PDL BioPharma Inc. (NASDAQ:PDLI),...
BC Week In Review | Feb 3, 2017
Company News

Scancell, Bonnie J. Addario Lung Cancer Foundation, Addario Lung Cancer Medical Institute deal

Scancell and the nonprofits partnered to conduct a Phase I/II trial of Scancell's SCIB2 in patients with non-small cell lung cancer (NSCLC). The trial will start in 2018 and will be completed about 18 months...
BioCentury | Jul 11, 2016
Finance

Ground up

Steve Edelson, Senior Editor   As the third quarter gets under way, biotech is shaking off the hangover of the Brexit vote while facing the overhang of the November election in the U.S. Fifteen bankers...
BC Week In Review | Jun 27, 2016
Clinical News

SCIB1: Phase I/II halted

Scancell suspended dosing in the open-label, dose-escalation, U.K. Phase I/II SCIB1-001 trial evaluating up to 8 mg intramuscular SCIB1 given at weeks 0, 3, 6, 12 and 24 after the company’s analysis of the stored...
BC Week In Review | Apr 4, 2016
Financial News

Scancell completes placing and open offer

Scancell Holdings plc (LSE:SCLP; Xetra:SCP), Nottingham, U.K.   Business: Cancer   Date completed: 2016-04-01   Type: Placing and open offer   Raised: L6.1 million ($8.7 million)   Shares: 36 million   Price: 17p   Shares...
BC Week In Review | Mar 28, 2016
Company News

Scancell, Karolinska Institute deal

Scancell and the institute partnered to use Scancell’s Moditope technology to evaluate citrullinated proteins to treat cancer and rheumatoid arthritis (RA). Scancell’s Moditope technology stimulates production of CD4+ T cells using citrullinated tumor-associated peptide epitopes...
BC Week In Review | Sep 21, 2015
Company News

ImmunID, Scancell deal

The companies will use ImmunID’s ImmunTraCkeR test to predict which patients will respond to Scancell’s SCIB1 , a cancer vaccine comprising the melanoma antigen tyrosinase-related protein 2 ( TRP-2 ; TYRP2 ; DCT ) and two helper T...
BC Week In Review | Jul 27, 2015
Clinical News

SCIB1: Completed Phase I/II enrollment

Scancell completed enrollment of 35 patients with resected stage III/IV metastatic melanoma in an open-label, dose-escalation, U.K. Phase I/II trial evaluating 4 mg intramuscular SCIB1 given at weeks 0, 3, 6, 12 and 24. Scancell...
BC Week In Review | Jun 8, 2015
Clinical News

SCIB1: Updated Phase I/II data

Updated data from 16 patients with fully resected stage III/IV metastatic melanoma in an open-label, U.K. Phase I/II trial showed that 4 mg intramuscular SCIB1 given at weeks 0, 3, 6, 12 and 24 led...
Items per page:
1 - 10 of 57